After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
MLYS belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Mineralys Therapeutics Inc is $2.91B. A total of 0.61 million shares were traded on the day, compared to an average of 1.52M shares.
In the most recent transaction, Rodman David Malcom sold 11,367 shares of MLYS for 36.00 per share on Sep 15 ’25. After the transaction, the Chief Medical Officer now owns 81,524 company shares. In a previous transaction on Sep 15 ’25, Rodman David Malcom bought 11,367 shares at 36.00 per share.
Among the insiders who bought shares, AKKARAJU SRINIVAS acquired of 588,235 shares on Sep 04 ’25 at a per-share price of $25.50. This resulted in the Director holding 588,235 shares of MLYS after the transaction. In another insider transaction, RA CAPITAL MANAGEMENT, L.P. bought 1,176,470 shares at $25.50 per share on Sep 04 ’25. Company shares held by the Director now total 5,456,521.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, MLYS has a high of $41.09 and a low of $8.24.
As of this writing, MLYS has an earnings estimate of -$0.64 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.51 per share and a lower estimate of -$0.74. The company reported an EPS of -$1.13 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. MLYS’s latest balance sheet shows that the firm has $10.61M in Cash & Short Term Investments as of fiscal 2021. There were $4.50M in debt and $5.05M in liabilities at the time. Its Book Value Per Share was $4.77, while its Total Shareholder’s Equity was -$22.93M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MLYS is Buy with a score of 4.56.
